The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

Much has been made of what a disruption the Act would be to American biotech companies, who have come to rely on relatively cheap Chinese contractors and suppliers. However, the grandfather clause ...

Do added that Chinese companies could bring those low prices to the US and undercut American drugmakers. China's biotech industry still carries big risks Chinese drug startups are shaking up the ...

While this is encouraging, it is important to note that a 2019 IQVIA Institute report found that 64% of FDA-approved drugs in 2018 (via Fierce Biotech) originated from emerging biopharma companies.

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

In this conversation, the Business Journal invites Cadrenal Founder & CEO Quang Pham to talk about the biopharmaceutical industry and financing.